Loading...

RLAY RELAY THERAPEUTICS INC Expansion Plans 8-K Filing

RLY

RLY

RELAY THERAPEUTICS INC

(RLAY)

2026 8-K

Clinical Trial Update

Bylaws Amendment

Financial Results

FDA Designation Granted

Financial Statements

Lease Amendments

Financial Results

Conference Announcement

Clinical Data Update

Financial Results

Clinical Data Release

Financial Results Announcement

Termination of Agreement

Collaboration and New Programs

Financial Results Announcement

Financial Results Announcement

Private Placement

Financial Results Announcement

Clinical Data Announcement

Earnings Reports

Financial Results Announcement

Financial Results Announcement

Investor Conferences

External Links:

On February 3, 2026, Relay Therapeutics announced that the FDA granted Breakthrough Therapy designation for zovegalisib (RLY-2608) combined with fulvestrant, aimed at treating advanced breast cancer in patients with PIK3CA mutations. This event is significant for the company and carries a positive sentiment among equity investors.

AI Assistant

RELAY THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.